Harmony Biosciences Holdings Inc (HRMY)

$29.5

-1.76

(-5.63%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Harmony Biosciences Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 119.12M → 168.41M (in $), with an average increase of 10.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 38.46M → 26.60M (in $), with an average decrease of 30.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 54.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 253.0% return, outperforming this stock by 251.6%

Performance

  • $29.03
    $31.40
    $29.50
    downward going graph

    1.59%

    Downside

    Day's Volatility :7.55%

    Upside

    6.05%

    downward going graph
  • $18.61
    $39.27
    $29.50
    downward going graph

    36.92%

    Downside

    52 Weeks Volatility :52.61%

    Upside

    24.88%

    downward going graph

Returns

PeriodHarmony Biosciences Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
-8.24%
-1.1%
0.0%
6 Months
23.43%
6.7%
0.0%
1 Year
-6.38%
3.2%
-0.7%
3 Years
1.44%
17.2%
-21.3%

Highlights

Market Capitalization
1.7B
Book Value
$8.23
Earnings Per Share (EPS)
2.13
PE Ratio
14.35
Wall Street Target Price
41.63
Profit Margin
22.14%
Operating Margin TTM
23.87%
Return On Assets TTM
16.16%
Return On Equity TTM
29.63%
Revenue TTM
582.0M
Revenue Per Share TTM
9.79
Quarterly Revenue Growth YOY
31.3%
Gross Profit TTM
354.4M
EBITDA
216.4M
Diluted Eps TTM
2.13
Quarterly Earnings Growth YOY
-0.43
EPS Estimate Current Year
2.91
EPS Estimate Next Year
4.02
EPS Estimate Current Quarter
0.48
EPS Estimate Next Quarter
0.67

Analyst Recommendation

Buy
    80%Buy
    13%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Harmony Biosciences Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
2
2
3
Sell
1
1
00

Analyst Forecast

What analysts predicted

Upside of 41.12%

Current $29.50
Target $41.63

Technicals Summary

Sell

Neutral

Buy

Harmony Biosciences Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
-5.93%
23.43%
-6.38%
1.44%
-20.29%
Moderna, Inc.
Moderna, Inc.
1.62%
14.36%
-33.07%
-34.3%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.67%
7.24%
9.09%
88.02%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-7.48%
23.09%
47.7%
252.97%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.99%
6.03%
18.9%
82.63%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
14.35
14.35
NA
2.91
0.3
0.16
NA
8.23
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
Buy
$1.7B
-20.29%
14.35
22.14%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • Valor Management LLC

    19.76%
  • BlackRock Inc

    10.58%
  • FMR Inc

    9.30%
  • Vanguard Group Inc

    6.47%
  • Vivo Capital, LLC

    4.59%
  • State Street Corporation

    2.40%

Company Information

patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.

Organization
Harmony Biosciences Holdings Inc
Employees
246
CEO
Mr. Jeffrey S. Aronin
Industry
Health Technology

FAQs